AKESO (09926.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec9

Akeso Announces Significant Efficacy in Phase II Study of Cadonilimab for Resectable Gastric Cancer

07:51

CanSino Biologics Announces Latest Findings of HARMONi-6 Trial at 2025 ESMO Asia Congress

02:21

Dec7

CanAngen's 5 self-developed new drugs successfully enter the National Medical Insurance Catalog

03:30

Nov13

CITIC Securities Issues Positive Report on CanAngela's Pipeline

08:49

Nov10

Competition Between Kangkang Biotech and Ssan Pharmaceutical in PD-1/VEGF Bispecific Antibodies

04:30

Nov7

Akeso Announces Significant OS Improvement in Ivonescimab Study

18:27

Schedules & Filings

Schedules

Filings

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 772.48 M, Net Income -311.98 M, EPS -0.3502

Mar30

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 584.69 M, Net Income -146.77 M, EPS -0.1712

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 550.56 M, Net Income -128.19 M, EPS -0.1517

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change